Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sinead Kelly

Showing results (51-60 of 66) with videos related to

Pageof 7
Sort By:
Neuroimage|December 15, 2015
ENIGMA and the individual: Predicting factors that affect the brain in 35 countries worldwidePaul M Thompson, Ole A Andreassen, Alejandro Arias-Vasquez, et al.
Schizophrenia Research|October 7, 2017
The Genetics of Endophenotypes of Neurofunction to Understand Schizophrenia (GENUS) consortium: A collaborative cognitive and neuroimaging genetics projectGabriëlla A M Blokland, Elisabetta C Del Re, Raquelle I Mesholam-Gately, et al.
Schizophrenia Bulletin Open|August 27, 2025
Sample Ascertainment and Recruitment Sources in the Accelerating Medicines Partnership Schizophrenia ProgramJean Addington, Amy Shalev, Lu Liu, et al.
Schizophrenia Bulletin Open|August 27, 2025
Baseline Clinical Characterization of Participants in the Accelerating Medicines Partnership Schizophrenia ProgramJean Addington, Lu Liu, Monica Chu, et al.
Translational Psychiatry|May 31, 2020
ENIGMA MDD: seven years of global neuroimaging studies of major depression through worldwide data sharingLianne Schmaal, Elena Pozzi, Tiffany C Ho, et al.
Schizophrenia Bulletin|May 11, 2026
Premorbid adjustment problems, negative symptoms, and cognitive impairment in a large international sample at clinical high risk for psychosis: Findings from the Accelerating Medicines Partnership-SchizophreniaHenry R Cowan, Danielle Pratt, Jai L Shah, et al.
Schizophrenia (Heidelberg, Germany)|March 25, 2025
Cognitive assessment in the Accelerating Medicines Partnership® Schizophrenia Program: harmonization priorities and strategies in a diverse international sampleKelly Allott, Walid Yassin, Luis Alameda, et al.
Molecular Psychiatry|December 21, 2019
Altered white matter microstructural organization in posttraumatic stress disorder across 3047 adults: results from the PGC-ENIGMA PTSD consortiumEmily L Dennis, Seth G Disner, Negar Fani, et al.
Biological Psychiatry|November 25, 2018
Reply to: New Meta- and Mega-analyses of Magnetic Resonance Imaging Findings in Schizophrenia: Do They Really Increase Our Knowledge About the Nature of the Disease Process?Theo G M van Erp, Esther Walton, Derrek P Hibar, et al.
Molecular Psychiatry|February 2, 2019
Correction: Dose response of the 16p11.2 distal copy number variant on intracranial volume and basal gangliaIda E Sønderby, Ómar Gústafsson, Nhat Trung Doan, et al.
Pageof 7

Showing results (51-60 of 66) with videos related to

Sort By:
Pageof 7
Neuroimage|December 15, 2015
ENIGMA and the individual: Predicting factors that affect the brain in 35 countries worldwidePaul M Thompson, Ole A Andreassen, Alejandro Arias-Vasquez, et al.
Schizophrenia Research|October 7, 2017
The Genetics of Endophenotypes of Neurofunction to Understand Schizophrenia (GENUS) consortium: A collaborative cognitive and neuroimaging genetics projectGabriëlla A M Blokland, Elisabetta C Del Re, Raquelle I Mesholam-Gately, et al.
Schizophrenia Bulletin Open|August 27, 2025
Sample Ascertainment and Recruitment Sources in the Accelerating Medicines Partnership Schizophrenia ProgramJean Addington, Amy Shalev, Lu Liu, et al.
Schizophrenia Bulletin Open|August 27, 2025
Baseline Clinical Characterization of Participants in the Accelerating Medicines Partnership Schizophrenia ProgramJean Addington, Lu Liu, Monica Chu, et al.
Translational Psychiatry|May 31, 2020
ENIGMA MDD: seven years of global neuroimaging studies of major depression through worldwide data sharingLianne Schmaal, Elena Pozzi, Tiffany C Ho, et al.
Schizophrenia Bulletin|May 11, 2026
Premorbid adjustment problems, negative symptoms, and cognitive impairment in a large international sample at clinical high risk for psychosis: Findings from the Accelerating Medicines Partnership-SchizophreniaHenry R Cowan, Danielle Pratt, Jai L Shah, et al.
Schizophrenia (Heidelberg, Germany)|March 25, 2025
Cognitive assessment in the Accelerating Medicines Partnership® Schizophrenia Program: harmonization priorities and strategies in a diverse international sampleKelly Allott, Walid Yassin, Luis Alameda, et al.
Molecular Psychiatry|December 21, 2019
Altered white matter microstructural organization in posttraumatic stress disorder across 3047 adults: results from the PGC-ENIGMA PTSD consortiumEmily L Dennis, Seth G Disner, Negar Fani, et al.
Biological Psychiatry|November 25, 2018
Reply to: New Meta- and Mega-analyses of Magnetic Resonance Imaging Findings in Schizophrenia: Do They Really Increase Our Knowledge About the Nature of the Disease Process?Theo G M van Erp, Esther Walton, Derrek P Hibar, et al.
Molecular Psychiatry|February 2, 2019
Correction: Dose response of the 16p11.2 distal copy number variant on intracranial volume and basal gangliaIda E Sønderby, Ómar Gústafsson, Nhat Trung Doan, et al.
Pageof 7